These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2239575)

  • 1. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
    Olver I; Keefe D; Myers M
    Intern Med J; 2005 Jul; 35(7):405-8. PubMed ID: 15958110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
    Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A pilot study of low dose etoposide therapy for recurrenced prostate cancer in complicated over 75 years old stage D2 cases].
    Wada T; Onodera S; Tashiro K; Iizuka N; Asano K; Yanada S; Takeuchi H; Ohishi Y
    Gan To Kagaku Ryoho; 1996 Nov; 23(13):1851-4. PubMed ID: 8937498
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
    Ushiyama T; Ihara H; Kurita Y; Kageyama S; Ueda D; Mugiya S; Yamaguchi Y; Nakano M; Suzuki K; Kawabe K
    Hinyokika Kiyo; 1993 Dec; 39(12):1139-44. PubMed ID: 8285162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
    Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
    Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of etoposide for carcinoma of the prostate.
    Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
    Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination chemotherapy with UFT, etoposide, CDDP, adriamycin (FEPA) in advanced gastric cancer].
    Hayakawa M; Morise K; Sakai T; Thin K; Ando T; Kokubu K; Akatsuka Y; Sato Y; Tahara H; Kuwahara Y
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3393-8. PubMed ID: 2508565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thermochemotherapy of prostatic cancer].
    Hirai M
    Hinyokika Kiyo; 1991 Aug; 37(8):833-6. PubMed ID: 1720274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination chemotherapy with etoposide, mitomycin C, and cyclophosphamide in advanced non-small cell lung cancer].
    Homma T; Yoneda S; Fukuda Y; Nakata M; Noguchi Y; Yoshida S
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2399-403. PubMed ID: 3015045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intermittent intravenous high-dose cyclophosphamide therapy for advanced prostatic cancer with distant metastasis].
    Kyakuno M; Yamaguchi S; Matsumiya K; Osafune M
    Hinyokika Kiyo; 1989 Nov; 35(11):1865-9. PubMed ID: 2618884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.